Jazz Pharmaceuticals (JAZZ) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Jazz Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$4.27B

Latest Revenue (Q)

$1.05B

Main Segment (Y)

Xywav

Main Geography (Y)

UNITED STATES

Jazz Pharmaceuticals Revenue by Period

Jazz Pharmaceuticals Revenue by Year

Date	Revenue	Change
2025-12-31	$4.27B	4.88%
2024-12-31	$4.07B	6.12%
2023-12-31	$3.83B	4.78%
2022-12-31	$3.66B	18.26%
2021-12-31	$3.09B	30.91%
2020-12-31	$2.36B	9.34%
2019-12-31	$2.16B	14.32%
2018-12-31	$1.89B	16.82%
2017-12-31	$1.62B	8.79%
2016-12-31	$1.49B	12.32%
2015-12-31	$1.32B	12.95%
2014-12-31	$1.17B	34.44%
2013-12-31	$872.42M	48.88%
2012-12-31	$585.98M	115.21%
2011-12-31	$272.28M	56.68%
2010-12-31	$173.78M	35.29%
2009-12-31	$128.45M	90.26%
2008-12-31	$67.51M	3.39%
2007-12-31	$65.30M	45.58%
2006-12-31	$44.86M	109.20%
2005-12-31	$21.44M	100.00%
2004-12-31	-	-

Jazz Pharmaceuticals generated $4.27B in revenue during NA 2025, up 4.88% compared to the previous quarter, and up 180.56% compared to the same period a year ago.

Jazz Pharmaceuticals Revenue by Quarter

Date	Revenue	Change
2025-06-30	$1.05B	16.47%
2025-03-31	$897.84M	-17.49%
2024-12-31	$1.09B	3.15%
2024-09-30	$1.05B	3.04%
2024-06-30	$1.02B	13.51%
2024-03-31	$901.98M	-10.87%
2023-12-31	$1.01B	4.09%
2023-09-30	$972.14M	1.55%
2023-06-30	$957.32M	7.22%
2023-03-31	$892.81M	-8.16%
2022-12-31	$972.12M	3.35%
2022-09-30	$940.65M	0.83%
2022-06-30	$932.88M	14.64%
2022-03-31	$813.72M	-9.26%
2021-12-31	$896.73M	6.99%
2021-09-30	$838.12M	11.48%
2021-06-30	$751.81M	23.74%
2021-03-31	$607.58M	-8.71%
2020-12-31	$665.52M	10.76%
2020-09-30	$600.89M	6.84%
2020-06-30	$562.44M	5.18%
2020-03-31	$534.73M	-8.08%
2019-12-31	$581.74M	8.19%
2019-09-30	$537.70M	0.67%
2019-06-30	$534.13M	5.11%
2019-03-31	$508.19M	6.66%
2018-12-31	$476.46M	1.51%
2018-09-30	$469.37M	-6.22%
2018-06-30	$500.48M	12.57%
2018-03-31	$444.61M	1.88%
2017-12-31	$436.40M	5.96%
2017-09-30	$411.86M	4.43%
2017-06-30	$394.39M	4.88%
2017-03-31	$376.05M	-5.19%
2016-12-31	$396.62M	6.00%
2016-09-30	$374.18M	-1.83%
2016-06-30	$381.16M	13.44%
2016-03-31	$336.01M	-1.43%
2015-12-31	$340.88M	0.00%
2015-09-30	$340.87M	2.13%
2015-06-30	$333.75M	7.90%
2015-03-31	$309.30M	-5.74%
2014-12-31	$328.14M	7.03%
2014-09-30	$306.58M	5.27%
2014-06-30	$291.23M	17.95%
2014-03-31	$246.92M	4.73%
2013-12-31	$235.77M	1.56%
2013-09-30	$232.16M	11.48%
2013-06-30	$208.25M	6.12%
2013-03-31	$196.24M	6.82%
2012-12-31	$183.70M	4.67%
2012-09-30	$175.51M	35.49%
2012-06-30	$129.54M	19.49%
2012-03-31	$108.41M	29.78%
2011-12-31	$83.54M	13.98%
2011-09-30	$73.29M	13.51%
2011-06-30	$64.57M	26.90%
2011-03-31	$50.88M	-4.66%
2010-12-31	$53.37M	19.25%
2010-09-30	$44.75M	10.54%
2010-06-30	$40.49M	15.11%
2010-03-31	$35.17M	-8.13%
2009-12-31	$38.28M	24.26%
2009-09-30	$30.81M	-17.36%
2009-06-30	$37.28M	68.87%
2009-03-31	$22.08M	12.66%
2008-12-31	$19.59M	10.42%
2008-09-30	$17.75M	14.20%
2008-06-30	$15.54M	6.18%
2008-03-31	$14.63M	-5.45%
2007-12-31	$15.48M	-

Jazz Pharmaceuticals generated $1.05B in revenue during Q2 2025, up 16.47% compared to the previous quarter, and up 115.93% compared to the same period a year ago.

Jazz Pharmaceuticals Revenue Breakdown

Jazz Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 25	Dec 24	Dec 22	Dec 21	Dec 20
Xywav	$1.66B	$1.47B	$958.42M	$535.30M	$15.26M
Ziihera	$24.81M	$1.05M	-	-	-
Zepzelca	$307.31M	$320.32M	$269.91M	$246.81M	$90.38M
Xyrem	$146.03M	$233.82M	$1.02B	$1.27B	$1.74B
Vyxeos	$146.71M	$162.59M	$127.98M	$134.06M	$121.11M
Sativex	$16.28M	$18.88M	$16.82M	$12.71M	-
Rylaze/Enrylaze	$402.92M	$410.85M	-	-	-
Other Products	$14.17M	$11.47M	$6.64M	$9.80M	$6.84M
High Sodium AG Oxybate Product Royalty Revenue	$211.72M	$217.57M	-	-	-
Epidiolex/Epidyolex	$1.06B	$972.42M	$736.40M	$463.64M	-
Defitelio/Defibrotide	$199.39M	$216.56M	$194.29M	$197.93M	$195.84M
Product And Services, Product Sales Net Of Deductions	-	$3.82B	$3.64B	$3.08B	$2.35B
Total Oncology	-	$1.11B	-	-	-
Sunosi	-	-	$28.84M	$57.91M	$28.33M
Erwinaze And Erwinase	-	-	-	$69.38M	$147.14M
Neuroscience	-	-	$2.76B	$2.34B	$1.79B
Oncology	-	-	$873.84M	$733.81M	$554.46M
Product And Services, Royalties And Contract Revenue	-	-	$17.95M	$15.24M	$16.91M
Rylaze	-	-	$281.66M	$85.63M	-
Total Oxybate	-	-	$1.98B	$1.80B	$1.76B

Jazz Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 25: Xywav (39.59%), Epidiolex/Epidyolex (25.31%), Rylaze/Enrylaze (9.63%), Zepzelca (7.34%), High Sodium AG Oxybate Product Royalty Revenue (5.06%), Defitelio/Defibrotide (4.76%), Vyxeos (3.51%), Xyrem (3.49%), Ziihera (0.59%), Sativex (0.39%), and Other Products (0.34%).

Quarterly Revenue by Product

Product/Service	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
Xywav	$465.45M	$431.41M	$415.32M	$344.80M	$400.96M	$388.47M	$368.47M	$315.30M	$326.56M	$277.76M	$281.38M	$255.94M	$235.03M	$186.08M	$182.65M	$153.06M	$124.16M	$75.42M	-	-
Ziihera	$8.54M	$8.31M	$5.99M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Zepzelca	$90.44M	$79.30M	$74.54M	$63.03M	$78.33M	$85.84M	$81.05M	$75.10M	$70.35M	$67.18M	$71.97M	$70.32M	$68.28M	$59.34M	$64.84M	$71.71M	$55.92M	$54.33M	$53.44M	$36.94M
Xyrem	$37.78M	$35.66M	$35.35M	$37.24M	$49.29M	$58.11M	$62.18M	$64.23M	$159.77M	$178.13M	$247.50M	$256.04M	$269.42M	$247.50M	$288.76M	$307.33M	$334.18M	$335.55M	$439.27M	$447.81M
Vyxeos	$34.73M	$37.58M	$44.85M	$29.54M	$53.25M	$34.31M	$43.01M	$32.02M	$34.06M	$36.70M	$30.27M	$30.07M	$33.89M	$33.76M	$34.76M	$34.69M	$31.45M	$33.16M	$30.99M	$30.82M
Sativex	$1.50M	$4.75M	$4.62M	$5.41M	$5.17M	$4.59M	$6.38M	$2.73M	$2.81M	$7.10M	$4.72M	$3.22M	$4.14M	$4.74M	$4.65M	$6.10M	$1.96M	-	-	-
Rylaze/Enrylaze	$108.16M	$99.87M	$100.66M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Products	$2.84M	$2.14M	$4.41M	$4.78M	$2.97M	$2.23M	$2.70M	$3.57M	$3.42M	$3.43M	$3.07M	$1.00M	$1.63M	$943.00K	$1.03M	$3.34M	$2.64M	$2.78M	$1.60M	$1.87M
High Sodium AG Oxybate Product Royalty Revenue	$55.70M	$52.95M	$54.14M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Epidiolex/Epidyolex	$287.12M	$302.61M	$251.73M	$217.74M	$275.05M	$251.56M	$247.10M	$198.72M	$202.23M	$188.91M	$207.00M	$196.22M	$175.29M	$157.89M	$193.79M	$160.38M	$109.48M	-	-	-
Defitelio/Defibrotide	$58.87M	$51.75M	$48.11M	$40.66M	$57.65M	$65.82M	$45.42M	$47.68M	$46.11M	$39.08M	$40.65M	$49.45M	$54.70M	$49.49M	$42.51M	$57.70M	$48.10M	$49.62M	$55.45M	$50.24M
Other Royalty And Contract Revenues	-	$8.75M	$6.00M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Oncology	-	-	$274.15M	$229.45M	$291.76M	$284.75M	$277.31M	$257.55M	$252.21M	$228.89M	-	-	-	-	-	-	-	-	-	-
Product And Services, Product Sales Net Of Deductions	-	-	$985.57M	$839.42M	$1.03B	$989.71M	$964.14M	$842.10M	$946.99M	$884.22M	$967.53M	$935.77M	$928.30M	$809.84M	$892.88M	$834.25M	$748.34M	$603.53M	$661.30M	$596.95M
Rylaze	-	-	-	-	-	-	-	-	$101.69M	$85.93M	$80.97M	$73.51M	$72.95M	$54.22M	$64.95M	$20.67M	-	-	-	-
Sunosi	-	-	-	-	-	-	-	-	-	-	-	-	$12.97M	$15.88M	$14.93M	$19.25M	$12.12M	$11.61M	$8.71M	$9.12M
Total Oxybate	-	-	-	-	-	-	-	-	$486.33M	$455.89M	$528.88M	$511.98M	$504.45M	$433.58M	$471.42M	$460.40M	$458.35M	$410.97M	-	-
Oncology	-	-	-	-	-	-	-	-	-	-	$223.86M	$223.35M	$229.82M	$196.80M	$207.07M	$184.78M	$163.79M	$178.18M	-	-
Product And Services, Royalties And Contract Revenue	-	-	-	-	-	-	-	-	-	-	$4.60M	$4.89M	$4.58M	$3.88M	$3.85M	$3.87M	$3.47M	$4.05M	$4.21M	$3.94M
Neuroscience	-	-	-	-	-	-	-	-	-	-	$740.60M	$711.41M	$696.84M	$612.09M	$684.79M	$646.12M	$581.91M	$422.57M	-	-
Erwinaze And Erwinase	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$28.31M	$41.07M	$56.58M	$20.14M

Jazz Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Xywav (40.43%), Epidiolex/Epidyolex (24.94%), Rylaze/Enrylaze (9.40%), Zepzelca (7.86%), Defitelio/Defibrotide (5.11%), High Sodium AG Oxybate Product Royalty Revenue (4.84%), Xyrem (3.28%), Vyxeos (3.02%), Ziihera (0.74%), Other Products (0.25%), and Sativex (0.13%).

Jazz Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 25	Dec 24	Dec 22	Dec 21	Dec 20
Europe	$341.12M	$312.71M	$239.64M	$230.16M	$175.21M
UNITED STATES	$3.83B	$3.66B	$3.37B	$2.82B	$2.14B
Other Countries	$94.87M	$96.14M	$49.36M	$43.84M	$43.82M

Jazz Pharmaceuticals's latest annual revenue breakdown by geography, as of Dec 25: UNITED STATES (89.78%), Europe (7.99%), and Other Countries (2.22%).

Quarterly Revenue by Country

Country	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
Other Countries	$32.69M	$19.23M	$26.67M	$16.29M	$32.66M	$23.98M	$17.07M	$22.41M	$13.28M	$16.80M	$10.70M	$12.79M	$13.76M	$12.11M	$7.29M	$10.16M	$13.64M	$12.06M	$13.99M	$6.70M
UNITED STATES	$1.08B	$1.02B	$936.28M	$797.95M	$973.63M	$953.67M	$924.59M	$808.21M	$884.71M	$810.12M	$903.62M	$867.84M	$858.34M	$740.58M	$823.82M	$757.23M	$690.90M	$548.29M	$601.55M	$548.41M
Europe	$88.35M	$86.41M	$82.76M	$83.61M	$81.87M	$77.32M	$82.16M	$71.36M	$59.33M	$65.90M	$57.81M	$60.02M	$60.78M	$61.03M	$65.62M	$70.73M	$47.27M	$47.23M	$49.98M	$45.78M

Jazz Pharmaceuticals's latest quarterly revenue breakdown by geography, as of Dec 25: UNITED STATES (89.90%), Europe (7.37%), and Other Countries (2.73%).

Jazz Pharmaceuticals Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
JAZZ	Jazz Pharmaceuticals	$4.27B	$1.05B
HALO	Halozyme Therapeutics	$1.40B	$354.26M
MDGL	Madrigal Pharmaceuticals	$958.40M	$287.27M
AXSM	Axsome Therapeutics	$638.50M	$170.99M
CAI	Caris Life Sciences	$294.01M	$216.83M
RYTM	Rhythm Pharmaceuticals	$189.76M	$51.30M
CYTK	Cytokinetics	$88.04M	$66.77M
MRUS	Merus	$36.13M	$12.15M
RNA	Avidity Biosciences	$18.75M	$12.47M
NUVL	Nuvalent	-	-
ABVX	Abivax	-	-

JAZZ Revenue FAQ

What is Jazz Pharmaceuticals’s yearly revenue?

Jazz Pharmaceuticals's yearly revenue for 2025 was $4.27B, representing an increase of 4.88% compared to 2024. The company's yearly revenue for 2024 was $4.07B, representing an increase of 6.12% compared to 2023. JAZZ's yearly revenue for 2023 was $3.83B, representing an increase of 4.78% compared to 2022.

What is Jazz Pharmaceuticals’s quarterly revenue?

Jazz Pharmaceuticals's quarterly revenue for Q2 2025 was $1.05B, a 16.47% increase from the previous quarter (Q1 2025), and a 2.14% increase year-over-year (Q2 2024). The company's quarterly revenue for Q1 2025 was $897.84M, a -17.49% decrease from the previous quarter (Q4 2024), and a -0.46% decrease year-over-year (Q1 2024). JAZZ's quarterly revenue for Q4 2024 was $1.09B, a 3.15% increase from the previous quarter (Q3 2024), and a 7.53% increase year-over-year (Q4 2023).

What is Jazz Pharmaceuticals’s revenue growth rate?

Jazz Pharmaceuticals's revenue growth rate for the last 3 years (2023-2025) was 11.30%, and for the last 5 years (2021-2025) was 37.92%.

What are Jazz Pharmaceuticals’s revenue streams?

Jazz Pharmaceuticals's revenue streams in c 25 are Xywav, Ziihera, Zepzelca, Xyrem, Vyxeos, Sativex, Rylaze/Enrylaze, Other Products, High Sodium AG Oxybate Product Royalty Revenue, Epidiolex/Epidyolex, and Defitelio/Defibrotide. Xywav generated $1.66B in revenue, accounting 39.59% of the company's total revenue, up 12.48% year-over-year. Ziihera generated $24.81M in revenue, accounting 0.59% of the company's total revenue, up 2260.61% year-over-year. Zepzelca generated $307.31M in revenue, accounting 7.34% of the company's total revenue, down -4.06% year-over-year. Xyrem generated $146.03M in revenue, accounting 3.49% of the company's total revenue, down -37.54% year-over-year. Vyxeos generated $146.71M in revenue, accounting 3.51% of the company's total revenue, down -9.77% year-over-year. Sativex generated $16.28M in revenue, accounting 0.39% of the company's total revenue, down -13.77% year-over-year. Rylaze/Enrylaze generated $402.92M in revenue, accounting 9.63% of the company's total revenue, down -1.93% year-over-year. Other Products generated $14.17M in revenue, accounting 0.34% of the company's total revenue, up 23.55% year-over-year. High Sodium AG Oxybate Product Royalty Revenue generated $211.72M in revenue, accounting 5.06% of the company's total revenue, down -2.69% year-over-year. Epidiolex/Epidyolex generated $1.06B in revenue, accounting 25.31% of the company's total revenue, up 8.92% year-over-year. Defitelio/Defibrotide generated $199.39M in revenue, accounting 4.76% of the company's total revenue, down -7.93% year-over-year.

What is Jazz Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Jazz Pharmaceuticals was Xywav. This segment made a revenue of $1.66B, representing 39.59% of the company's total revenue.